News - Takeda Pharmaceuticals


Current filters:

Takeda Pharmaceuticals

Popular Filters

70 to 94 of 192 results

Takeda files for brentuximab vedotin approval in Japan; sanctioned by JPMA


Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) and its oncology subsidiary Millennium have…

AdcetrisAlinamin-F5Asia-PacificbrentuximabMillennium LaboratoriesOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Takeda expands Latin America footprint with new subsidiary in Ecuador


Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) says it is expanding its presence in Latin…

ManagementMarkets & MarketingPharmaceuticalSouth AmericaTakeda Pharmaceuticals

NPS Pharma regains rights to Revestive and Preotact from Takeda


USA-based NPS Pharmaceuticals (Nasdaq: NPSP) has re-gained the full worldwide rights from partner Takeda…

Anti-Arthritics/RheumaticsGastro-intestinalsGattexLicensingNatparaNPS PharmaceuticalsPharmaceuticalPreotactRevestiveTakeda Pharmaceuticals

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA


The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system…

EisaiEuropeFycompaGastro-intestinalsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Takeda taps Resolve for lupus disease candidate


Takeda Pharmaceutical (TYO: 4502), Japan's largest drugmaker, has licensed rights to a series of autoimmune…

LicensingPharmaceuticalRare diseasesResolve TherapeuticsRSLV-132Takeda Pharmaceuticals

Takeda and Affymax recall all lots of anemia drug Omontys


US drugmaker Affymax (Nasdaq: AFFY) and its licensee, Japan's Takeda Pharmaceutical (TYO: 4502), said…

AffymaxMarkets & MarketingNorth AmericaOmontysPharmaceuticalRegulationTakeda Pharmaceuticals

Takeda called on to take corrective action over Alinamin-F5 marketing and manufacturing


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) revealed it has received an Order for Corrective…

Alinamin-F5Asia-PacificPharmaceuticalProductionRegulationTakeda Pharmaceuticals

Takeda, Shionogi, Ono Pharma and Mitsubishi Tanabe post nine-month results


Takeda Pharmaceuticals (TYO: 4502), Japan's largest drugmaker, has reported nine-month 2013 results with…

FinancialMitsubishi TanabeOno PharmaceuticalPharmaceuticalShionogiTakeda Pharmaceuticals

Torrey Pines Institute collaborates with Takeda unit


The Torrey Pines Institute for Molecular Studies, a non-profit institute dedicated to conducting basic…

Envoy TherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

Japan launches for Lotriga and Argamate


Norway's Pronova BioPharma (OSE: PRON.OL), recently the subject of a $845 million takeover bid from Germany's…

ArgamateAstellas PharmaCardio-vascularLotrigaMarkets & MarketingNephrology and HepatologyNorth AmericaPharmaceuticalPronova BioPharmaSanwa KagakuTakeda Pharmaceuticals

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers


A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Infinity amends PI3K-delta, gamma accord with Millennium


US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) says it has amended its development and…

BiotechnologyFinancialInfinity PharmaceuticalsIPI-145LicensingMillennium PharmaceuticalsPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches


The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing…

BiotechnologyfulranumabGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalTakeda Pharmaceuticalstanezumabtapentadol

FDA grants Seattle Genetics' Adcetris orphan rating in MF


US biotech firm Seattle Genetics (Nasdaq: SGEN) says its Adcetris (brentuximab vedotin) has been granted…

AdcetrisBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Takeda debuts Hodgkin lymphoma drug Adcetris in UK


Japan's largest drugmaker, Takeda Pharmaceuticals (TYO: 4502), this morning announced the launch UK of…

AdcetrisEuropeMarkets & MarketingOncologyPharmaceuticalTakeda Pharmaceuticals

Another acquisition for Takeda, Envoy Therapeutics for up to $140 million


Takeda Pharmaceutical (TYO: 4502), Japan's largest drugmaker, has clearly not quenched its thirst for…

Envoy TherapeuticsMergers & AcquisitionsNeurologicalPharmaceuticalTakeda Pharmaceuticals

European Commission grants conditional approval for Adcetris


Millennium, a wholly owned subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502)…

AdcetrisBiotechnologyEuropeMillennium PharmaceuticalsOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Takeda's leadership as Japan's largest drugmaker set to decline, says DR


Based on full-year 2011 sales, Japan's Takeda Pharmaceutical (TYO: 4502) maintained its position as the…

Asia-PacificAstellas PharmaFinancialPharmaceuticalResearchTakeda Pharmaceuticals

70 to 94 of 192 results

Back to top